Related Experiment Videos
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
R Li1, P D Sutphin, D Schwartz
1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Oncogene
|July 29, 1998
Summary
Mutant p53 (a tumor suppressor) can hinder cancer cell death from chemotherapy. Understanding specific p53 mutations is crucial for effective cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Loss of normal p53 function frequently impairs cancer cell response to conventional therapies.
- Over half of human cancers harbor p53 mutations, necessitating investigation into their role in drug-induced apoptosis.
Purpose of the Study:
- To explore the involvement of mutant p53 in drug-induced apoptosis.
- To evaluate the interplay between p53-dependent and p53-independent apoptotic pathways.
- To elucidate the function of mutant p53 in modulating these processes.
Main Methods:
- Utilized M1/2 myeloid p53 non-producer cells and derived clones expressing a temperature-sensitive (ts) mutant p53.
- Investigated apoptosis induced by chemotherapeutic drugs (doxorubicin, cisplatin) and gamma-irradiation.
- Assessed the effect of Actinomycin D on apoptosis.
Main Results:
- Apoptosis induced by DNA damage was enhanced in cells with wild-type p53 compared to p53 non-producer cells.
- Clones expressing mutant p53 exhibited increased resistance to apoptosis induced by DNA-damaging agents.
- Actinomycin D abrogated the apoptosis-restraining effect of mutant p53.
Conclusions:
- Loss of wild-type p53 function reduces apoptosis rates.
- p53 mutations may confer a gain of function that interferes with chemotherapy-induced apoptosis.
- Tailoring cancer therapy requires understanding the specific relationship between p53 mutations and selected chemotherapeutics.